Overview

Dexanabinol in Severe Traumatic Brain Injury

Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
Each year a large number of patients are hospitalized at Shock Trauma Centers with severe head injuries. Bleeding into and swelling of these patients' brains may cause compression of vital structures, disability and death. Sometimes surgery is needed. Unfortunately, the investigators have no medication to treat the bad effects of head trauma. Part of the brain damage is due to toxic chemicals (including one called glutamate) that are released by the damaged nerves. Dexanabinol may prevent some of the bad effects of glutamate on the brain and may protect the brain against uncontrollable swelling and death.
Phase:
Phase 3
Details
Lead Sponsor:
Pharmos
Treatments:
Dronabinol
HU 211